Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination

Medical therapy for clinical benign prostatic hyperplasia (BPH) has advanced significantly in the last 2 decades. Many new α1 antagonists and 5α reductase inhibitors (5ARi) are now commercially available. The practicing urologist must decide on the most appropriate medication for his patients, takin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shum, Cheuk Fan, Lau, Weida, Teo, Chang Peng Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717968/
https://www.ncbi.nlm.nih.gov/pubmed/29264229
http://dx.doi.org/10.1016/j.ajur.2017.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717968/
https://www.ncbi.nlm.nih.gov/pubmed/29264229
http://dx.doi.org/10.1016/j.ajur.2017.06.002

Ejemplares similares